Showing results (131-140 of 260) with videos related to

Sort By:
Pageof 26
Journal of Pathology Informatics|December 23, 2024
Towards interactive AI-authoring with prototypical few-shot classifiers in histopathologyPetr Kuritcyn, Rosalie Kletzander, Sophia Eisenberg, et al.
Wiener Klinische Wochenschrift|July 26, 2018
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
Hepatology (Baltimore, Md.)|October 14, 2011
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathwaysCoral Ho, Chunmei Wang, Sandra Mattu, et al.
Hepatology (Baltimore, Md.)|January 25, 2012
V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesisMatthias Evert, Diego F Calvisi, Katja Evert, et al.
Scientific Reports|February 10, 2016
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in miceJunjie Hu, Li Che, Lei Li, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53Diego F Calvisi, Maria M Simile, Sara Ladu, et al.
Cancers|July 7, 2019
Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular CarcinomaXianqiong Liu, Junjie Hu, Xinhua Song, et al.
Hepatology (Baltimore, Md.)|August 23, 2014
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in miceChunmei Wang, Antonio Cigliano, Lijie Jiang, et al.
Cancers|October 27, 2022
Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA ConsortiumFlorian Lüke, Florian Haller, Kirsten Utpatel, et al.
British Journal of Cancer|December 26, 2022
Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer CentreAlexander Scheiter, Frederik Hierl, Florian Lüke, et al.
Pageof 26